Detalles de la búsqueda
1.
Treatment responses to basal insulin glargine 300 U/ml and glargine 100 U/ml in newly defined subphenotypes of type 2 diabetes: A post hoc analysis of the EDITION 3 randomized clinical trial.
Diabetes Obes Metab
; 26(2): 503-511, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37860918
2.
Comparative efficacy and safety of Gla-300 versus IDegAsp in insulin-naïve people with type 2 diabetes mellitus uncontrolled on oral anti-diabetics.
Diabetes Obes Metab
; 25(9): 2495-2504, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37312665
3.
Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C-peptide levels in insulin-naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial.
Diabetes Obes Metab
; 22(9): 1664-1669, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32314521
4.
Fasting C-peptide, a biomarker for hypoglycaemia risk in insulin-naïve people with type 2 diabetes initiating basal insulin glargine 100 U/mL.
Diabetes Obes Metab
; 22(3): 315-323, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31608548
5.
Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0.
Diabetes Obes Metab
; 21(2): 321-329, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30520217
6.
Hypoglycaemia risk in the first 8 weeks of titration with insulin glargine 100 U/mL in previously insulin-naive individuals with type 2 diabetes mellitus.
Diabetes Obes Metab
; 20(12): 2894-2898, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29943493
7.
The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL.
Cardiovasc Diabetol
; 16(1): 66, 2017 05 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-28526014
8.
Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes.
Diabetes Obes Metab
; 19(11): 1546-1554, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28449412
9.
Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs. intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents--a randomized, prospective, crossover, open clinical trial.
Health Qual Life Outcomes
; 13: 77, 2015 Jun 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-26055391
10.
Responses to Basal Insulin Glargine (300 U/mL and 100 U/mL) with or Without Pre-prandial Insulin in Pre-treated Subphenotypes of Type 2 Diabetes: Insights from a Post Hoc Analysis.
Diabetes Ther
; 2024 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38879736
11.
Response to insulin glargine 100 U/mL treatment in newly-defined subgroups of type 2 diabetes: Post hoc pooled analysis of insulin-naïve participants from nine randomised clinical trials.
Prim Care Diabetes
; 17(4): 379-385, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37142540
12.
Distribution and characteristics of newly-defined subgroups of type 2 diabetes in randomised clinical trials: Post hoc cluster assignment analysis of over 12,000 study participants.
Diabetes Res Clin Pract
; 190: 110012, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35863553
13.
Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.
Lancet
; 371(9618): 1073-84, 2008 Mar 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-18374840
14.
Glycaemic responses in Asian and non-Asian people with type 2 diabetes initiating insulin glargine 100â¯units/mL: A patient-level pooled analysis of 16 randomised controlled trials.
Diabetes Res Clin Pract
; 135: 199-205, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-29179974
15.
Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy.
Diabetes Res Clin Pract
; 124: 57-65, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-28092788
16.
Recombinant Human Insulin in Global Diabetes Management - Focus on Clinical Efficacy.
Eur Endocrinol
; 13(1): 21-25, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-29632602
17.
Recombinant Human Insulins - Clinical Efficacy and Safety in Diabetes Therapy.
Eur Endocrinol
; 12(1): 12-17, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-29632581
18.
Equivalent Recombinant Human Insulin Preparations and their Place in Therapy.
Eur Endocrinol
; 11(1): 10-16, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-29632560
19.
Insulin Glulisine in Pregnancy - Experience from Clinical Trials and Post-marketing Surveillance.
Eur Endocrinol
; 11(1): 17-20, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-29632561
20.
Insulin glargine compared with premixed insulin for management of insulin-naïve type 2 diabetes patients uncontrolled on oral antidiabetic drugs: the open-label, randomized GALAPAGOS study.
J Diabetes Complications
; 29(6): 838-45, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25981123